Apogenix GmbH The company is a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, based either on the targeted modulation of apoptosis (programmed cell death) or on a blockade of the invasive growth of tumour cells. The lead product candidate of the company, APG101, entered a controlled Phase II proof-of-concept study with glioblastoma patients in December 2009.